Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1

Trial StartPositive

AI Analysis

Summary

Viking Therapeutics has started testing a weight loss drug candidate that operates through a mechanism beyond GLP-1 agonism, positioning itself as a competitor to established players like Eli Lilly and Novo Nordisk in the obesity treatment market.

Clinical Trial Data

Importance:6/10

Sentiment:

0.70

weight lossGLP-1 alternativeclinical trialViking Therapeuticscompetitive landscape

Related Companies

$VKTX

Read the original article

Published by yahoo_finance on July 18, 2026 8:05 PM

Read Original